Pharmaceuticals
The Global Risks of America’s “Most-Favored-Nation” Drug Pricing Policy
The U.S. government’s reliance on the most-favored-nation (MFN) pricing model — tying drug costs to the lowest price paid by other countries — is a politically appealing but structurally flawed solution.
The Global Risks of America’s “Most-Favored-Nation” Drug Pricing Policy
